High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients

@article{Velden2004HighCL,
  title={High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients},
  author={V. H. J. van der Velden and Nancy Boeckx and Inge Jedema and J G te Marvelde and Patricia G. Hoogeveen and M. A. Boogaerts and J J M van Dongen},
  journal={Leukemia},
  year={2004},
  volume={18},
  pages={983-988}
}
Gemtuzumab ozogamicin (Mylotarg®) induces remission in approximately 30% of relapsed AML patients. We previously demonstrated that gemtuzumab infusion results in near-complete CD33 saturation in peripheral blood, and that saturating gemtuzumab levels result in continuous binding and internalization of gemtuzumab due to renewed CD33 expression. We now demonstrate that a high CD33-antigen load in peripheral blood is an independent adverse prognostic factor, likely due to peripheral consumption of… CONTINUE READING
28 Citations
18 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Internalization and cell cycle dependent killing of leukemic cells by gemtuzumab ozogamicin (GO): rationale for application in CD33 negative malignancies with endocytic capacity

  • I Jedema, RMY Barge, VHJ van der Velden, BA Nijmeijer, JG te Marvelde, JJM van Dongen
  • Leukemia
  • 2004

Mylotarg therapy in acute myeloid leukemia: mechanism of action and implications for future treatment protocols

  • VHJ van der Velden, MS Berger, JJM. van Dongen
  • Haematol Blood Transfusion
  • 2003

treatment of acute myeloid leukemia

  • Y Alvarado, A Tsimberidou, H Kantarjian, J Cortes, G Garcia-Manero, S Faderl
  • Cancer
  • 2003

Similar Papers

Loading similar papers…